Printer Friendly

Virta Health Names Former CMS Head Berwick Joins Board of Directors.

M2 PHARMA-August 4, 2017-Virta Health Names Former CMS Head Berwick Joins Board of Directors

(C)2017 M2 COMMUNICATIONS

- US-based online specialty medical clinic Virta Health has named former Centers for Medicare and Medicaid Services Administrator Dr. Don Berwick to its board of directors, the company said.

Drawing on decades of research, including that of its founders, Virta's approach to type 2 diabetes reversal puts physicians and coaches into the pockets of patients through their smartphones to support everyday decisions, minute by minute.

Berwick is president emeritus and a senior fellow at the Institute for Healthcare Improvement.

A pediatrician by training, Berwick has served on the faculty of Harvard Medical School and the Harvard School of Public Health, as well as Boston's Children's Hospital Medical Center, Massachusetts General Hospital, and the Brigham and Women's Hospital. He was vice chair of the US Preventive Services Task Force, the first independent member of the American Hospital Association's board of Trustees, and chair of the National Advisory Council of the Agency for Healthcare Research and Quality.

He served on the Institute of Medicine's Governing Council and on president Clinton's Advisory Commission on Consumer Protection and Quality in the Healthcare Industry.

Virta said it reverses type 2 diabetes by lowering hemoglobin A1c (a measure of blood sugar) while reducing or eliminating medications in an online setting with continuous, remote care.

The Virta Clinic provides physician supervision, a dedicated health coach, app and biomarker tracking tools, a community of peers, and a personalised nutrition and care plan based on each patient's biochemistry, medications, and lifestyle.

The company's debut in March 2017 came on the heels of a peer-reviewed study that demonstrated Virta was successful in reversing type 2 diabetes in half of its clinical trial patients and eliminating or reducing insulin in 87% of patients in 10 weeks.

Virta said it is continuing to follow participants as part of its two-year clinical trial, and at six months, retention remains at 89 % and weight loss has continued -- patients lost 12 % of their body weight on average.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 4, 2017
Words:350
Previous Article:Caradigm Adds Insignia Health's Patient Activation Measure Survey into Its Care Management Solution.
Next Article:Swift Biosciences Launches New Indexed Adapters for Sequencing Larger Numbers of Samples.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters